reason report
investor day highlight potenti disrupt landscap pt
bottom line melinta mlnt nr infecti diseas id
deal complet mdco becom pure play inclisiran
hypercholesterolemia despit slow launch
monoclon antibodi due high cost poor complianc
mdco highlight reason inclisiran much brighter
prospect vast ldl-c lower market unmet need
remain high mdco leverag lower cog deliv
cost-effect drug trial may better captur
therapeut benefit fourier near term expect
mdco share move headlin includ repatha
mp praluent regn/sni op op sale trend
upcom odyssey outcom data long-term investor
may find today stock price attract entri point
reiter op lower pt previous reflect
new id busi model follow melinta deal lower
enrol studi suggest high unmet need
lower low-dens lipoprotein cholesterol ldl-c despit
perhap payor restrict antibodi
market wait long pivot inclisiran data sinc
today mdco announc much faster-than-expect enrol
link studi also expect complet
enrol soon today mdco present new data
dose inclisiran result absolut ldl-c reduct
mg/dl respect day despit
avail statin antibodi rapid enrol suggest
high unmet need popul view
outcom trial design improv upon
shortcom fourier trial despit clear biolog rational
inhibit hypercholesterolemia short durat follow-
prove hurt fourier data compar fourier
yr follow-up median follow pt yr
effect captur long-term therapeut benefit particularli
modifi endpoint link safeti concern either
inhibit low ldl-c level believ data may
better delin treatment benefit inclisiran repatha
fourier turn would make stronger health benefit argument
payor could lead better reimburs fewer denial
continu next page
dcf discount rate
net debt total capit
compani inform leerink partner llc research
revenu mm ep estim gaap
pleas refer page import disclosur price chart analyst certif
leverag lower cog better complianc inclisiran could
cost-effect option payor mdco present independ
cost-effect analys suggest antibodi valu
rang per kazi per fonarow lower
manufactur cost inclisiran mdco expect abl deliv
cost-effect therapi obtain higher market penetr
addit inclisiran less frequent dose support much
better pt complianc antibodi requir once-
twice-monthli inject accord michael sherman harvard
pilgrim healthcar doubt efficaci safeti
antibodi cost effect main determin
mdco inclisiran potenti formid competitor
adjust model reflect melinta deal lower tax
assumpt divestitur id busi melinta link
mdco stand receiv royalti net sale minocin orbactiv
vabomer meanwhil restructur effort expect lower
opex line management guidanc anticip current cash
suffici lastli lower tax rate assumpt
mdco follow us corpor tax reform
rate mdco share outperform medicin compani mdco evolv
hospital-focus specialti pharmaceut compani late stage biotech product develop
year mdco deliv impress revenu growth lead product angiomax
bivalirudin becam domin anticoagul use percutan coronari intervent
pci stent procedur angiomax composition-of-matt patent expir
model gener eros risk-adjust basi mdco acquir
gram-negative-target antibiot vabomer formerli
carbav receiv fda approv mdco recent reach agreement
melinta mlnt nr includ infecti diseas product orbactiv minocin iv
vabomer therebi provid non-dilut financ mdco concurr streamlin
compani oper behind inclisiran hypercholesterolemia pure play
inclisiran hypercholesterolemia market evolut reimburs patient
uptak dynam proprotein convertas subtilisin/kexin type drug
repatha mp praluent regn/sni op op provid read-through mdco
stock lastli manag demonstr commit unlock sharehold valu
repres seri recent transact mp mlnt nr
estim fair valu month mdco share sum-of-the-part dcf
analysi includ net cash overal use wacc discount rate sinc risk
involv drug develop regulatori approv alreadi handicap
probability-weight revenu estim pipelin asset appli termin growth
rate continu assum peak vabomer revenu mdco
receiv royalti net sale melinta probability-weight peak inclisiran revenu
risk associ clinic develop commerci activ impact mdco valuat
earn power signific invest necessari develop inclisiran trial delay
dilut financ and/or failur deliv non-dilut financ plan continu weak
broader market pose risk
incom loss oper
sale busi
loss extinguish debt
sale busi
equiv end period
purchas secur
total estim chang net cash
net sale product
sec file leerink partner llc estim
enrol complet
enrol complet
enrol complet
second dsmb review
first patient dose
dsmb review
pre-fil syring switch
